Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661035 · ClinicalTrials.gov registry record · Phase 2
Allo HSCT Using RIC for Hematological Diseases
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT02661035 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 156 participants.
The verdict
NCT02661035, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus and mycophenolate mofetil (MMF) with a non-myeloablative preparative regimen in persons with hematologic malignancies.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Allopurinol
- DRUG ATG
- RADIATION TBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2023-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661035
The ClinicalTrials.gov registry entry for NCT02661035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02661035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661035 about?
NCT02661035 is a clinical study titled "Allo HSCT Using RIC for Hematological Diseases". This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic...
What is the current status of trial NCT02661035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2017-03-09. Estimated completion is 2023-05-29.
What interventions are being tested in trial NCT02661035?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Allopurinol (DRUG), ATG (DRUG), TBI (RADIATION).
Who is sponsoring clinical trial NCT02661035?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.